期刊
PLOS ONE
卷 10, 期 6, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0128381
关键词
-
资金
- Gertrud-Kusen-Foundation fellowship
- Rosetrees Trust
- NIHR Biomedical Research Centre funding to University College London Hospitals and UCL
- Bill and Melinda Gates Foundation
- Wellcome Trust
- UK Engineering and Physical Sciences Research Council (EPSRC) [EP/G027005]
- Roche Pharma
- Engineering and Physical Sciences Research Council [EP/G027005/1] Funding Source: researchfish
- EPSRC [EP/G027005/1] Funding Source: UKRI
The CCR5 receptor plays a role in several key physiological and pathological processes and is an important therapeutic target. Inhibition of the CCR5 axis by passive or active immunisation offers one very selective strategy for intervention. In this study we define a new linear epitope within the extracellular domain of CCR5 recognised by two independently produced monoclonal antibodies. A short peptide encoding the linear epitope can induce antibodies which recognise the intact receptor when administered colinear with a tetanus toxoid helper T cell epitope. The monoclonal antibody RoAb 13 is shown to bind to both cells and peptide with moderate to high affinity (6x10 boolean AND 8 and 1.2x10(7) M-1 respectively), and binding to the peptide is enhanced by sulfation of tyrosines at positions 10 and 14. RoAb13, which has previously been shown to block HIV infection, also blocks migration of monocytes in response to CCR5 binding chemokines and to inflammatory macrophage conditioned medium. A Fab fragment of RoAb13 has been crystallised and a structure of the antibody is reported to 2.1 angstrom resolution.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据